Tandem Diabetes Care (TNDM) Projected to Post Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $254.99 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.16. The company had revenue of $247.22 million during the quarter, compared to analysts’ expectations of $240.41 million. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.66) earnings per share. On average, analysts expect Tandem Diabetes Care to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Tandem Diabetes Care Stock Performance

Shares of TNDM opened at $20.20 on Wednesday. The company has a current ratio of 3.58, a quick ratio of 3.07 and a debt-to-equity ratio of 4.54. The firm has a market cap of $1.38 billion, a PE ratio of -14.43 and a beta of 1.54. The company’s 50 day simple moving average is $16.73 and its 200-day simple moving average is $18.88. Tandem Diabetes Care has a 12-month low of $9.98 and a 12-month high of $29.65.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of institutional investors have recently added to or reduced their stakes in the business. Freestone Grove Partners LP acquired a new position in Tandem Diabetes Care during the 3rd quarter worth approximately $22,706,000. First Light Asset Management LLC acquired a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at approximately $23,947,000. Marshall Wace LLP acquired a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at approximately $19,244,000. Balyasny Asset Management L.P. purchased a new stake in shares of Tandem Diabetes Care in the fourth quarter valued at approximately $5,776,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Tandem Diabetes Care by 17.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,683,400 shares of the medical device company’s stock valued at $37,001,000 after buying an additional 252,028 shares in the last quarter.

Analyst Ratings Changes

Several analysts recently commented on the stock. Weiss Ratings downgraded shares of Tandem Diabetes Care from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft started coverage on shares of Tandem Diabetes Care in a research report on Tuesday, June 23rd. They set a “hold” rating and a $15.50 price objective on the stock. Citigroup reaffirmed a “neutral” rating and issued a $17.00 target price (down from $22.00) on shares of Tandem Diabetes Care in a report on Thursday, May 28th. The Goldman Sachs Group set a $21.00 target price on shares of Tandem Diabetes Care in a research note on Wednesday, May 27th. Finally, Bank of America lowered their price target on Tandem Diabetes Care from $35.00 to $25.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of “Hold” and an average price target of $28.73.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.